CEM(SZ:002980)2024-04-19 13:07Financial Performance - The company's revenue for Q1 2024 was CNY 152,527,488.90, representing a 0.86% increase compared to CNY 151,231,759.11 in the same period last year[5] - Net profit attributable to shareholders increased by 30.30% to CNY 27,443,957.16 from CNY 21,062,048.07 year-on-year[5] - Basic and diluted earnings per share rose by 25.00% to CNY 0.20, compared to CNY 0.16 in the same period last year[5] - Net profit for Q1 2024 reached CNY 27,602,496.15, up from CNY 21,139,197.68 in the same period last year, indicating a growth of approximately 30.5%[26] - The total comprehensive income for the first quarter of 2024 was CNY 26,899,074.67, an increase from CNY 20,853,145.93 in the same period last year, representing a growth of approximately 28.9%[27] Cash Flow - The net cash flow from operating activities surged by 187.38% to CNY 58,382,114.91, up from CNY 20,315,499.86 in the previous year[5] - Cash inflows from operating activities totaled CNY 189,432,504.99, up from CNY 161,812,321.26, marking an increase of about 17.1%[28] - The net cash flow from investment activities decreased to CNY 12,709,583.43 from CNY 43,289,082.82, a decline of approximately 70.7%[30] - The net cash flow from financing activities was negative at CNY -69,953,219.12, compared to a positive CNY 52,538,800.01 in the previous year[31] - The company reported a total cash outflow from operating activities of CNY 131,050,390.08, which is lower than the previous year's CNY 141,496,821.40, indicating a decrease of approximately 7.5%[30] Assets and Liabilities - Total assets decreased by 1.69% to CNY 1,329,739,913.87 from CNY 1,352,557,543.80 at the end of the previous year[5] - Current assets totaled CNY 886,294,141.88, down from CNY 970,807,262.05, representing a decline of approximately 8.7%[20] - The total liabilities decreased to CNY 254,410,038.44 from CNY 293,777,311.55, a reduction of approximately 13.4%[22] - The company's cash and cash equivalents slightly decreased to CNY 276,255,408.14 from CNY 276,380,780.76, indicating a stable liquidity position[20] Investments and Expenses - Investment income surged by 265.52% to CNY 619,034.47, primarily from the maturity of trading financial assets[10] - Research and development expenses increased to CNY 16,526,876.04 from CNY 15,088,487.17, reflecting a commitment to innovation[25] - Sales expenses increased by 45.59% to CNY 13,436,920.27, driven by higher personnel and marketing costs[10] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,340[12] - Major shareholder Yuan Jianmin holds 52.80% of shares, totaling 72,000,000 shares[12] - The company has 5% or more shareholders, including Yuan Jianmin and Che Haixia, with significant holdings[13] - The company has established relationships among major shareholders, indicating potential coordinated actions[13] Share Repurchase and Incentive Plans - The company plans to repurchase shares with a total amount not less than RMB 40 million and not exceeding RMB 80 million, with a maximum price of RMB 29 per share[16] - The repurchase period is set for up to 12 months from the board's approval date[17] - The company has completed the initial grant registration of the 2022 restricted stock incentive plan, granting 3,021,500 shares at a price of RMB 18.16 per share[15] - The company has not yet completed the share repurchase process as of the report date[17] Certifications and Product Development - The company received EU MDR certification for its electronic thermometer, electronic blood pressure monitor, and pulse oximeter products[14] - The company reported a significant increase in goodwill by 172.20%, reaching CNY 20,755,049.91 due to the acquisition of a subsidiary's asset group[9] - The company reported a significant increase in inventory, which rose to CNY 278,838,080.30 from CNY 268,765,799.42, an increase of about 3.99%[20]